Influence of CYP2C9 Genotype on Clinical Efficacy of Tenoxicam
NCT04182191
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
89
Enrollment
OTHER
Sponsor class
Conditions
Molar, Third
Pain
Interventions
DRUG:
Tenoxicam
Sponsor
University of Sao Paulo